See for Yourself: Sales by Product in 1-3Q FY13
Sales Number in $M
FY2013___Q-Jun_Q-Sep_Q-Dec
Namenda_368.4__367.6__345.8
Bystolic___107.8__106.5__108.8
Viibryd_____37.4___39.9___40.6
Sevella____26.7___26.2___25.6
Diliresp____17.8___19.5___17.5
Teflaro_____9.4____10.0___11.5
Comment: no blockbuster except Namenda (Cliff in 2016)!!!!
EPS(est)__$0.24__($0.01)__($0.14)
EPS______$0.21__$0.08___($0.16)
Outlook FY13: low end of $0.45-0.60, i.e., QMar13 EPS at least $0.32 -- versus Consensus $0.13